Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-((8-hydroxyquinolin-7-yl)(2-nitrophenyl)methylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one
- Development stage
- Preclinical
- Lead developer
- Milind College of Science
- Modality
- Small Molecules
01
Overview
4-((8-hydroxyquinolin-7-yl)(2-nitrophenyl)methylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one, also referred to as compound 4b, is a small molecule synthesized through a Betti-type reaction involving the one-pot condensation of 2-nitrobenzaldehyde, 4-aminoantipyrine, and 8-hydroxyquinoline. Developed by researchers at the Milind College of Science, this compound has been evaluated for its anthelmintic and anti-inflammatory properties. It acts as an inhibitor of cyclooxygenase (COX) isoenzymes, which prevents the synthesis of prostanoids involved in inflammation and parasite survival. In in-vitro studies, the compound demonstrated potent anthelmintic activity, with efficacy in inducing paralysis and death in helminth parasites comparable to the reference drug albendazole. Furthermore, compound 4b satisfies Lipinski's rule of five, suggesting favorable pharmacokinetic properties for potential oral development.
- Other names
- 4-((8-hydroxyquinolin-7-yl)(2-nitrophenyl)methylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
02
Targets
COX
Beyond the preview
Go deeper on 4-((8-hydroxyquinolin-7-yl)(2-nitrophenyl)methylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-((8-hydroxyquinolin-7-yl)(2-nitrophenyl)methylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one.